CD44 and triple-negative breast carcinoma: The MAPK8 inhibitor JNK-IN-8 has demonstrated therapeutic potential, since it synergizes with lapatinib to induce cell death in triple-negative breast cancer (TNBC) cells and significantly improves survival in mouse models with TNBC xenografts [55].